The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.

Since 1989, World Hemophilia Day has been celebrated annually on April 17. An estimated 1 in 1,000 have a bleeding disorder; yet 75 percent receive inadequate or no treatment. This year’s celebration brings attention to the women and girls in our community who live with a bleeding disorder. The WFH invites everyone to show their support for the millions of women and girls affected by bleeding disorders by sharing their story.

People around the world living with hemophilia and other inherited bleeding disorders rely upon the lifesaving plasma protein therapies produced by PPTA member companies. PPTA works globally to advocate on behalf of patients with these disorders.

PPTA also collaborates with patient organizations in both Europe and the U.S., including the Committee of Ten Thousand (COTT), Hemophilia Federation of America (HFA), the National Hemophilia Foundation (NHF), the World Federation of Hemophilia (WFH) and the European Hemophilia Consortium (EHC), through its stakeholder meetings, publications, and advocacy events. Today, these therapies enable patients with plasma protein disorders to lead active, productive lives. The progress has been remarkable, but there is much work to be done. World Hemophilia Day shines a much-needed spotlight on the important needs of the bleeding disorder community, as well as the need for raising awareness, early diagnosis and effective treatment.

About the Plasma Protein Therapeutics Association The Plasma Protein Therapeutics Association (PPTA) represents the commercial manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by millions of people worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80 percent of the plasma protein therapies in the U.S. and 60 percent of those manufactured in Europe. PPTA works globally to:

Advocate for access to and affordability of therapies for patients

Engage in constructive dialogue with regulatory agencies

Administer standards programs that help ensure the quality and safety of plasma collection and manufacturing to protect the health of donors and patients.

Collaborate with patient advocacy organizations

Membership

PPTA News

The article, “How Blood-Plasma Companies Target the Poorest Americans,” by H. Luke Shaefer and Analidis Ochoa, published in The Atlantic on March 15, was unfair to plasma donors as well as to individuals living with rare, genetic, and chronic diseases who rely on access to plasma protein therapies. Plasma donors are due our gratitude and respect, not sweeping negative characterizations.

Highlights from the 2018 IPPC +

Mr. Jan M. Bult, President & CEO, PPTA, opened the well-attended IPPC 2018 by welcoming the more than 300 attendees to Budapest. PPTA thanks its sponsors who help make the IPPC possible every year. Download the IPPC app (available in the Apple AppStore and Android Market/Google Play) for Apple or Android devices) for a complete list of sessions and many of the presentations.

GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS +

Budapest, HUNGARY (March 13)– The Plasma Protein Therapeutics Association (PPTA) today unveiled its new global initiative, “How Is Your Day?” –Making the difference with plasma proteins, in conjunction with the annual International Plasma Protein Congress. “How Is Your Day?” will focus on differentiating these unique therapies from traditional pharmaceuticals and building awareness of the value they provide for people living with rare, life-threatening, chronic, and genetic diseases.